HUE050962T2 - Hiszton demetiláz inhibitor szubsztituált (E)-N'-(1-feniletilidén)-benzohidrazid származékok - Google Patents
Hiszton demetiláz inhibitor szubsztituált (E)-N'-(1-feniletilidén)-benzohidrazid származékokInfo
- Publication number
- HUE050962T2 HUE050962T2 HUE12823540A HUE12823540A HUE050962T2 HU E050962 T2 HUE050962 T2 HU E050962T2 HU E12823540 A HUE12823540 A HU E12823540A HU E12823540 A HUE12823540 A HU E12823540A HU E050962 T2 HUE050962 T2 HU E050962T2
- Authority
- HU
- Hungary
- Prior art keywords
- inhiitors
- phenylethylidene
- substituted
- histone demethylase
- benzohydrazide analogs
- Prior art date
Links
- 102000008157 Histone Demethylases Human genes 0.000 title 1
- 108010074870 Histone Demethylases Proteins 0.000 title 1
- HAUVWRQIVOPGOE-FOWTUZBSSA-N n-[(e)-1-phenylethylideneamino]benzamide Chemical class C=1C=CC=CC=1C(/C)=N/NC(=O)C1=CC=CC=C1 HAUVWRQIVOPGOE-FOWTUZBSSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
- C07C311/46—Y being a hydrogen or a carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161523801P | 2011-08-15 | 2011-08-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE050962T2 true HUE050962T2 (hu) | 2021-01-28 |
Family
ID=47715455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE12823540A HUE050962T2 (hu) | 2011-08-15 | 2012-08-15 | Hiszton demetiláz inhibitor szubsztituált (E)-N'-(1-feniletilidén)-benzohidrazid származékok |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US8987335B2 (enExample) |
| EP (1) | EP2744330B1 (enExample) |
| JP (1) | JP6122006B2 (enExample) |
| KR (1) | KR101983537B1 (enExample) |
| CN (1) | CN103929960B (enExample) |
| AU (1) | AU2012296639B2 (enExample) |
| BR (1) | BR112014003382B1 (enExample) |
| CA (1) | CA2843609C (enExample) |
| CY (1) | CY1123345T1 (enExample) |
| DK (1) | DK2744330T3 (enExample) |
| EA (1) | EA026389B1 (enExample) |
| ES (1) | ES2821548T3 (enExample) |
| HK (1) | HK1200052A1 (enExample) |
| HR (1) | HRP20201433T1 (enExample) |
| HU (1) | HUE050962T2 (enExample) |
| IL (1) | IL230728A (enExample) |
| IN (1) | IN2014CN00961A (enExample) |
| LT (1) | LT2744330T (enExample) |
| MX (1) | MX356486B (enExample) |
| PL (1) | PL2744330T3 (enExample) |
| PT (1) | PT2744330T (enExample) |
| SG (1) | SG2014009609A (enExample) |
| SI (1) | SI2744330T1 (enExample) |
| SM (1) | SMT202000551T1 (enExample) |
| WO (1) | WO2013025805A1 (enExample) |
| ZA (1) | ZA201400881B (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9266838B2 (en) | 2011-08-15 | 2016-02-23 | University Of Utah Research Foundation | Substituted (E)-N′-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhibitors |
| HRP20170358T1 (hr) | 2012-10-02 | 2017-04-21 | Gilead Sciences, Inc. | Inhibitori histonskih demetilaza |
| ES2670864T3 (es) * | 2013-02-27 | 2018-06-01 | Gilead Sciences, Inc. | Inhibidores de histonas desmetilasas |
| WO2014164708A1 (en) * | 2013-03-12 | 2014-10-09 | Quanticel Pharmaceuticals, Inc. | Histone dementhylase inhibitors |
| JP6525162B2 (ja) * | 2013-06-19 | 2019-06-05 | ザ ユニバーシティ オブ ユタ リサーチ ファウンデイション | ヒストン脱メチル化酵素阻害剤としての置換（ｅ）−ｎ’−（１−フェニルエチリデン）ベンゾヒドラジド類似体 |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| US9493442B2 (en) | 2014-02-13 | 2016-11-15 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| KR102421235B1 (ko) | 2014-02-13 | 2022-07-15 | 인사이트 코포레이션 | Lsd1 저해제로서 사이클로프로필아민 |
| TWI720451B (zh) | 2014-02-13 | 2021-03-01 | 美商英塞特控股公司 | 作為lsd1抑制劑之環丙胺 |
| US10807944B2 (en) | 2014-04-04 | 2020-10-20 | University Of Florida Research Foundation, Inc. | HDAC inhibitor compounds and methods of treatment |
| US20170144965A1 (en) * | 2014-06-05 | 2017-05-25 | The University Of Kansas | Marmelin analogs and methods of use in cancer treatment |
| US9758523B2 (en) | 2014-07-10 | 2017-09-12 | Incyte Corporation | Triazolopyridines and triazolopyrazines as LSD1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| SG11201701182VA (en) | 2014-08-27 | 2017-03-30 | Gilead Sciences Inc | Compounds and methods for inhibiting histone demethylases |
| EP2993175A1 (en) | 2014-09-05 | 2016-03-09 | IEO - Istituto Europeo di Oncologia Srl | Thienopyrroles as histone demethylase inhibitors |
| CN106146361A (zh) * | 2015-03-16 | 2016-11-23 | 四川大学 | 茚-1-亚基磺酰基苯甲酰肼衍生物及其制备方法和用途 |
| SG11201708047UA (en) | 2015-04-03 | 2017-10-30 | Incyte Corp | Heterocyclic compounds as lsd1 inhibitors |
| JP6855466B2 (ja) | 2015-06-12 | 2021-04-07 | オリゾン ジェノミックス ソシエダッド アノニマ | Ｌｓｄ１阻害剤に関連するバイオマーカーおよびそれらの使用 |
| WO2017013061A1 (en) | 2015-07-17 | 2017-01-26 | Oryzon Genomics, S.A. | Biomarkers associated with lsd1 inhibitors and uses thereof |
| CN110402244B (zh) | 2015-08-12 | 2023-02-03 | 因赛特公司 | Lsd1抑制剂的盐 |
| SG10201913331VA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for use in the treatment of solid tumors |
| ES3042059T3 (en) | 2016-03-16 | 2025-11-18 | Oryzon Genomics Sa | Methods to determine kdm1a target engagement and chemoprobes useful therefor |
| SG10202010414QA (en) * | 2016-04-22 | 2020-11-27 | Incyte Corp | Formulations of an lsd1 inhibitor |
| EP3246330A1 (en) | 2016-05-18 | 2017-11-22 | Istituto Europeo di Oncologia S.r.l. | Imidazoles as histone demethylase inhibitors |
| EP3487490A4 (en) * | 2016-07-19 | 2020-01-15 | The General Hospital Corporation | TARGETING COMPOUNDS OF CANCER STEM CELLS |
| US20190256929A1 (en) | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| EP3535420A1 (en) | 2016-11-03 | 2019-09-11 | Oryzon Genomics, S.A. | Biomarkers for determining responsiveness to lsd1 inhibitors |
| MA51507A (fr) | 2016-12-09 | 2020-11-11 | Constellation Pharmaceuticals Inc | Marqueurs pour un traitement personnalisé du cancer avec des inhibiteurs de lsd1 |
| CN106831489B (zh) * | 2017-03-23 | 2018-04-17 | 郑州大学 | 苯环丙胺酰腙类化合物、制备方法及其应用 |
| CN110996949A (zh) | 2017-08-03 | 2020-04-10 | 奥瑞泽恩基因组学股份有限公司 | 用于治疗行为改变的方法 |
| AU2018316542B2 (en) | 2017-08-18 | 2023-02-16 | Istituto Europeo Di Oncologia (Ieo) S.R.L. | Indole derivatives as histone demethylase inhibitors |
| WO2019068326A1 (en) | 2017-10-05 | 2019-04-11 | Université D'aix-Marseille | INHIBITORS OF LSD1 FOR THE TREATMENT AND PREVENTION OF CARDIOMYOPATHIES |
| WO2019226213A2 (en) | 2018-03-08 | 2019-11-28 | Incyte Corporation | AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| CN109793742A (zh) * | 2019-03-04 | 2019-05-24 | 四川大学华西医院 | 一种药物化合物应用 |
| CA3130638A1 (en) | 2019-03-20 | 2020-09-24 | Oryzon Genomics, S.A. | Methods of treating borderline personality disorder |
| CN109758442B (zh) * | 2019-03-20 | 2021-08-17 | 武汉大学 | 二芳基酰肼类化合物在制备抗流感病毒药物中的应用 |
| CN120837494A (zh) | 2019-03-20 | 2025-10-28 | 奥莱松基因组股份有限公司 | 使用kdm1a抑制剂如化合物伐菲德司他治疗注意缺陷多动症的方法 |
| EP3994280A1 (en) | 2019-07-05 | 2022-05-11 | Oryzon Genomics, S.A. | Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors |
| WO2022020804A1 (en) * | 2020-07-24 | 2022-01-27 | Salarius Pharmaceuticals Llc | Methods of inhibiting lysine-specific demethylase 1 (lsd-1) |
| EP3964204A1 (en) | 2020-09-08 | 2022-03-09 | Université d'Aix-Marseille | Lsd1 inhibitors for use in the treatment and prevention of fibrosis of tissues |
| KR20230167102A (ko) | 2021-04-08 | 2023-12-07 | 오리존 지노믹스 에스.에이. | 골수성 암 치료를 위한 lsd1 억제제의 조합물 |
| JP2025516647A (ja) | 2022-05-09 | 2025-05-30 | オリゾン・ゲノミクス・ソシエダッド・アノニマ | Ｌｓｄ１阻害薬を用いる悪性末梢神経鞘腫（ｍｐｎｓｔ）の治療法 |
| WO2023217784A1 (en) | 2022-05-09 | 2023-11-16 | Oryzon Genomics, S.A. | Methods of treating nf1-mutant tumors using lsd1 inhibitors |
| CN116077661B (zh) * | 2022-08-22 | 2024-09-27 | 沈阳药科大学 | Kdm1a抑制剂在制备治疗dnmt3a基因缺失癌症的药物中的用途 |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004525118A (ja) * | 2001-01-22 | 2004-08-19 | アルパイダ アーゲー | 新規ヒドラゾン類 |
| JP2002302472A (ja) * | 2001-01-31 | 2002-10-18 | Meiji Seika Kaisha Ltd | メイラード反応阻害剤 |
| CN100406006C (zh) | 2003-07-16 | 2008-07-30 | 株式会社医药分子设计研究所 | 皮肤色素沉着的治疗剂 |
| WO2006136008A1 (en) | 2005-05-24 | 2006-12-28 | University Health Network | Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer |
| TW200800145A (en) * | 2005-08-26 | 2008-01-01 | Dekk Tec Inc | Hydrazone agents to treat cutaneous lesions |
| WO2007056159A2 (en) | 2005-11-03 | 2007-05-18 | Redpoint Bio Corporation | Hydrazone derivatives and uses thereof |
| US8338464B2 (en) | 2006-11-30 | 2012-12-25 | Albert Einstein College Of Medicine Of Yeshiva University | Small molecule inhibitors of BCL6 |
| AU2008214338A1 (en) | 2007-02-02 | 2008-08-14 | Redpoint Bio Corporation | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release |
| JP2010523579A (ja) * | 2007-04-02 | 2010-07-15 | インスティテュート フォア ワンワールド ヘルス | Ｃｆｔｒ阻害剤化合物およびそれらの使用 |
| WO2009027349A2 (en) * | 2007-08-24 | 2009-03-05 | Oryzon Genomics Sa | Treatment and prevention of neurodegenerative diseases |
| AR070898A1 (es) * | 2008-03-18 | 2010-05-12 | Solvay Pharm Bv | Derivados de arilsulfonil pirazolin carboxamidina como antagonistas de 5-ht6 |
| EP2307440A4 (en) | 2008-07-01 | 2012-12-19 | Zacharon Pharmaceuticals Inc | HEPARAN SULFATE INHIBITORS |
| US20120010075A1 (en) * | 2009-01-14 | 2012-01-12 | Dow Agrosciences Llc | Synergistic fungicidal compositions including hydrazone derivatives and copper |
| CA2727890A1 (en) | 2010-01-13 | 2011-07-13 | Norbert Kartner | Compounds, compositions and treatments for v-atpase related diseases |
-
2012
- 2012-08-15 JP JP2014526170A patent/JP6122006B2/ja active Active
- 2012-08-15 PL PL12823540T patent/PL2744330T3/pl unknown
- 2012-08-15 LT LTEP12823540.5T patent/LT2744330T/lt unknown
- 2012-08-15 KR KR1020147006969A patent/KR101983537B1/ko active Active
- 2012-08-15 PT PT128235405T patent/PT2744330T/pt unknown
- 2012-08-15 BR BR112014003382-0A patent/BR112014003382B1/pt active IP Right Grant
- 2012-08-15 US US13/586,603 patent/US8987335B2/en active Active
- 2012-08-15 SM SM20200551T patent/SMT202000551T1/it unknown
- 2012-08-15 HK HK15100490.8A patent/HK1200052A1/xx unknown
- 2012-08-15 SG SG2014009609A patent/SG2014009609A/en unknown
- 2012-08-15 MX MX2014001842A patent/MX356486B/es active IP Right Grant
- 2012-08-15 WO PCT/US2012/050948 patent/WO2013025805A1/en not_active Ceased
- 2012-08-15 EA EA201490453A patent/EA026389B1/ru unknown
- 2012-08-15 SI SI201231841T patent/SI2744330T1/sl unknown
- 2012-08-15 CA CA2843609A patent/CA2843609C/en active Active
- 2012-08-15 HR HRP20201433TT patent/HRP20201433T1/hr unknown
- 2012-08-15 AU AU2012296639A patent/AU2012296639B2/en active Active
- 2012-08-15 IN IN961CHN2014 patent/IN2014CN00961A/en unknown
- 2012-08-15 CN CN201280050736.9A patent/CN103929960B/zh active Active
- 2012-08-15 DK DK12823540.5T patent/DK2744330T3/da active
- 2012-08-15 ES ES12823540T patent/ES2821548T3/es active Active
- 2012-08-15 EP EP12823540.5A patent/EP2744330B1/en active Active
- 2012-08-15 HU HUE12823540A patent/HUE050962T2/hu unknown
-
2014
- 2014-01-30 IL IL230728A patent/IL230728A/en active IP Right Grant
- 2014-02-05 ZA ZA2014/00881A patent/ZA201400881B/en unknown
-
2015
- 2015-02-16 US US14/623,370 patent/US9555024B2/en not_active Expired - Fee Related
-
2020
- 2020-09-14 CY CY20201100866T patent/CY1123345T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201400881B (en) | Substituted (e)-n'-(1-phenylethylidene)benzohydrazide analogs as histone demethylase inhiitors | |
| IL243200A0 (en) | Converted analogs of (e)-n'-(1-phenylethylidene)benzohydrazide as histone demethylase inhibitors | |
| LT3930330T (lt) | Judėjimo vektorių skirtumų entropinis kodavimas | |
| HUE049603T2 (hu) | Berendezés mozgásinformáció levezetésére | |
| DK2725936T3 (da) | Stødafledningsmekanisme | |
| HRP20170783T1 (hr) | Spoj guanidina | |
| CO6990683A2 (es) | Mascarilla para polvo | |
| FR2990699B1 (fr) | Cassettes d'expression procaryotes regulees par le stress | |
| IL225350A0 (en) | Converted benzamide compounds | |
| PL2772490T3 (pl) | Aminoalkilo-podstawiona pochodna n-tienylobenzamidu | |
| ZA201309245B (en) | Novel fluoroergoline analogs | |
| ZA201308401B (en) | Substituted benzamide derivatives | |
| DK2828668T3 (da) | Hydroxy-sphingomyelin 22:1 som biomarkør for sund aldring | |
| EP2916840A4 (en) | SUBSTITUTED GEMCITABIN ARYL AMID ANALOGUE | |
| BR112013031218A2 (pt) | protetores solares | |
| BR112014002365A2 (pt) | interleucina-7 (il-7) | |
| BR112013031107A2 (pt) | protetores solares | |
| EP2793858A4 (en) | NATURAL COMPOSITIONS FOR MULTIPLE RELEASE AND RE-USE | |
| GB201222939D0 (en) | New Antiviral Compound 2 | |
| BR112013031538A2 (pt) | protetores solares | |
| BR112013031217A2 (pt) | protetores solares | |
| ES1076782U8 (es) | Cordón o cinta para cabezales friegasuelos | |
| UA21783S (uk) | Етикетка для чаю «премія» | |
| DK2785675T5 (da) | 5,5-dimethyl-2-propyl-hexahydro-2,4a-methanonaphthalen-1-on som duftmiddel |